ADAM20

Across TCGA pan-cancer cohorts, ADAM20 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ADAM20 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ADAM20 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADAM20 expression acts as an unfavorable survival marker.

BLCA, LUAD, and COAD are the cancer types where ADAM20 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	IV	0.090	0.469	.009	12	view →
LUAD	OS	Median	III,IV	0.083	0.680	<.001	12	view →
COAD	OS	Median	All	0.168	0.799	.009	12	view →
READ	DFS	Median	All	0.084	0.845	<.001	9	view →
PRAD	DFS	Median	All	0.153	0.888	<.001	6	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →
HNSC	OS	Median	II,III,IV	0.286	0.651	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ADAM20–BLCA (DFS)

Open the BLCA breakdown →